Loading...
Market
What will be the percentage weight loss efficacy of Roche's CT-996 in Phase II trials?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Official results from Roche's Phase II clinical trial reports
Story
Roche Announces Positive Phase I Results for CT-996 Obesity Drug, Shares Rise 7.5%
Jul 17, 2024, 10:22 AM
Roche has announced positive early results from a Phase I clinical trial of its oral GLP-1 receptor agonist, CT-996, aimed at treating obesity. The trial demonstrated meaningful weight reduction in patients with obesity, showing a placebo-adjusted mean weight loss of 6.1% within four weeks. The drug, which can potentially be dosed without regard to meal timing, is seen as a promising candidate for oral weight maintenance therapy following weight loss induced by injectables. Following the announcement on Wednesday, Roche's shares (RHHBY, ROG.CH) rose by 7.5% in premarket trading. Conversely, shares of competitors Novo Nordisk and Eli Lilly fell by 3.1% and 3.4% respectively. The drug was acquired as part of Roche's $3.1 billion takeover of Carmot.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% weight loss • 25%
5% to 10% weight loss • 25%
10% to 15% weight loss • 25%
More than 15% weight loss • 25%
Mean weight loss < 5% • 25%
Mean weight loss 5% to 7% • 25%
Mean weight loss 7% to 9% • 25%
Mean weight loss > 9% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Mounjaro leads • 25%
Competitor A leads • 25%
Competitor B leads • 25%
Other drug leads • 25%